Jörg Chromik

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Uwe Platzbecker, Ulrich Germing, Katharina S. Götze et al. · The Lancet Oncology · 2017 · 288 citations

Medicine, Hematology, Pharmacology +8

Enasidenib vs conventional care in older patients with late-stage mutant-<i>IDH2</i> relapsed/refractory AML: a randomized phase 3 trial

Stéphane de Botton, Pau Montesinos, Andre C. Schuh et al. · Blood · 2022 · 115 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype

Claudia Haferlach, Tamara Alpermann, Susanne Schnittger et al. · Blood · 2011 · 66 citations · Full text

Life Sciences, Hematology, Oncology +17

Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T‐cell acute lymphoblastic leukemia and lymphoma

Gautam Borthakur, Giovanni Martinelli, Emmanuel Raffoux et al. · Cancer · 2020 · 37 citations

Medicine, Pharmacology, Pharmacotherapy +17

Identification of Adult Patients With Classical Dyskeratosis Congenita or Cryptic Telomere Biology Disorder by Telomere Length Screening Using Age-modified Criteria

Mareike Tometten, Martin Kirschner, Robert Meyer et al. · HemaSphere · 2023 · 22 citations · Full text

Medicine, Genetics, Hematology +17